Latest Content

Slated to run through December 31, 2027, the Medicare GLP-1 Bridge was originally supposed to run for only 6 months.

Jody Agena, PharmD, discusses staffing, communication, and operational readiness for implementing complex oncology therapies.

The FDA advisory committee supports Moderna’s mRNA-1010 flu vaccine for adults 50-plus, with an August 5 PDUFA decision pending for mFlusiva.

A secret shopper study found 9 in 10 online GLP-1 sellers issued prescriptions, often with minimal screening for eating disorders or clinical risk.

A Brown University–led review synthesizes GDMT, comorbidity management, and emerging therapies into a hospital-based framework for HFpEF.

Adults treated with insulin showed sustained A1C improvements and fewer acute care visits among patients whose CGM was initiated in primary care compared with similar patients who did not initiate CGM.

Roughly one-fifth of supplemental indications were approved many years after a drug’s initial launch, many of which target populations with high unmet medical needs.

emtelligent turns unstructured data into coded clinical insights, powering Optum and oncology workflows to improve trial screening, EHR-to-EDC transfer, and decisions.

ViroMissile shares phase 1 IDOV-Safe oncolytic virus results, showing IV activity in pMMR/MSS metastatic colorectal cancer and fueling US phase 2 plans.